I wrote an article on Stem Cells (STEM) for Seeking Alpha last week. The article (found here) talked about how the stock ran up from results of an Alzheimers study. When that article was published, shares were up 70%, before they ultimately were up over 100% in one day. The stock is a "penny stock", with a price under $5 a share, and saw huge volume that led to the large percentage increase.
From StemCells website, here is the current pipeline:
Spinal Cord Injury - Clinical Development
PMD - Clinical Development
AMD - Pre-Clinical
Alzheimer's - Pre-Clinical
Stroke - Pre-Clinical
Liver Metabolic Disorders - Pre-Clinical
Hepatitis C - Research
As you can see, StemCells is working on different areas of the body focusing on the eyes, spinal cord, and brain. These all represent areas critical to survival for humans. The areas are all also underserved by the medical community with treatments.
Are you looking for small biotech companies that could jump on positive news? Follow along with my monthly newsletter coming in Auguust or September. The newsletter will be free or under $5 a month. You can email me at firstname.lastname@example.org or follow this site for more information. The newsletter will have an area dedicated to drug stocks. Sample trackable portfolios will also be included, where StemCells will most likely have a position for the long term.